CPHI 8-K: CPHI subsidiary acquires patent for $6.93M via stock; issues 12.6M shares

CPHI subsidiary acquires patent for $6.93M via stock; issues 12.6M shares

CHINA PHARMA HOLDINGS, INC.

Hainan Helpson acquires patent for Prinsepia Utilis Esterol Sublingual Tablets from Xiaoyan Zhang.

Transfer price of $6.93M paid as 12.6M restricted shares of CPHI at $0.55 per share.

Patent granted 2018, expires 2038; transferor provides technical services.

Shares issued under Regulation S exemption as offshore transaction.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Agreement with Xiaoyan Zhang valued at $6.93 million (effective 2026-02-26).

Action: entry
Agreement: asset purchase
Counterparty: Xiaoyan Zhang
Value: $6.93 million
Effective: 2026-02-26

Exact text from the filing

On February 26, 2026 (the “Signing Date”), Hainan Helpson Medical & Biotechnology Co., Ltd (“ Helpson ”), a wholly owned subsidiary of China Pharma Holdings, Inc. (the “ Company ”), entered into a Technology Transfer Agreement (the “ Agreement ”) with Xiaoyan Zhang (the “ Transferor ”). The Transferor owns an invention patent of an Prinsepia Utilis Esterol Sublingual Tablets and Method for Its Preparation (the “ Invention Patent ”). Pursuant to the Agreement, the Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated third party shall provide relevant technical services, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services. The transfer price as contemplated by the Agreement is $6.93 million, which will be paid in the form of common stock of the Company, par value $0.001 per share, at $0.55 per share.

View on SEC.gov